Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elinzanetant bioavailability study in healthy women
NCT07229404Phase 1Completed
- Sponsor
- Bayer
- Start
- Nov 2025
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of elinzanetant in vasomotor symptoms (6 arms), sponsored by Bayer. Primary endpoints: Area Under the Curve from 0 to 24 hours at multiple dosing, Maximum plasma concentration at multiple dosing at Day 7 and 1 more. Started Nov 2025; status: completed.
02
Drugs
elinzanetant
03
Conditions
vasomotor symptoms
Beyond the preview
Go deeper on NCT07229404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07229404.